A Double Blind, Randomised, Placebo Controlled Study of Farlutal in the Treatment of Weight Loss in Patients Undergoing Radiotherapy for Head and Neck Cancer
| ISRCTN | ISRCTN72126158 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN72126158 |
| Secondary identifying numbers | MPA8801 |
- Submission date
- 19/08/2002
- Registration date
- 19/08/2002
- Last edited
- 03/03/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Not Specified |
| Scientific title | |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Head and Neck Cancer |
| Intervention | 1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks 2. Group B: Placebo tablets twice daily for a maximum of 12 weeks |
| Intervention type | Other |
| Primary outcome measure | Not provided at time of registration |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 19/08/2000 |
| Completion date | 19/08/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Lower age limit | 18 Years |
| Sex | Not Specified |
| Target number of participants | Not provided at time of registration |
| Key inclusion criteria | 1. Aged >18 years 2. Squamous cell carcinoma of the head and neck 3. Not known to have or suspected of having early breast cancer 4. No known hypersensitivity to medroxyprogesterone acetate 5. No medical contraindications to treatment |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 19/08/2000 |
| Date of final enrolment | 19/08/2005 |
Locations
Countries of recruitment
- England
- Italy
- United Kingdom
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Sponsor information
Farmitalia Carlo Erba (Italy)
Industry
Industry
-
-
-
Italy
"ROR" |
https://ror.org/03htt2d69 |
|---|
Funders
Funder type
Not defined
Not provided at time of registration.
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
